In addition, they are also compatible with a recent work showing that CSF tau and p-tau181 levels, but not Aβ42 levels, predict subsequent rates of whole-brain and regional atrophy in AD over the next three years37. The gene discussed is MAPT; the disease is Alzheimer disease.